Advances in Strategies to Transport Nanoparticles Across the Blood–Brain Barrier for Drug Delivery into the Brain for the Treatment of Alzheimer’s Disease
Open accessThe DOI matches its Crossref record; 129 of the 129 references it cites were found in a registry or an index; 93 of the 168 sources its claims cite were checked for support.
Abstract
Different types of engineered nanoparticles have been demonstrated to be able to penetrate this barrier and serve as efficient drug delivery systems into the brain, making them a promising solution for future therapeutic development.
Overview
CoChat Summary
## TL;DR
This is a narrative review of nanoparticle-based strategies to move drugs across the blood–brain barrier for Alzheimer’s disease, with emphasis on surface functionalization, focused ultrasound, stimuli-responsive systems, exosomes, gene therapy, and magnetic nanoparticles. It concludes that these approaches are promising in preclinical studies but have not yet achieved clinical translation for AD.
## Key findings
- The review states that the blood–brain barrier is the main obstacle to AD drug delivery, and that engineered nanoparticles can improve targeting, loading capacity, bioavailability, and reduce systemic adverse effects.
- It identifies several strategies to enhance brain delivery: surface-functionalized nanoparticles, focused ultrasound (FUS) combined with microbubbles, stimuli-responsive nanoparticles, gene-therapy nanoparticles, exosome-mediated delivery, and magnetic nanoparticles.
- For physicochemical design, it reports that nanoparticles for brain delivery are generally considered suitable in the 100–200 nm range; very small particles (<30 nm) may be renally cleared, while larger ones (150–300 nm) may accumulate in liver and spleen.
- The paper notes that despite multiple encouraging preclinical examples, clinical application in trials is “nonexistent” for these advanced nanoparticle strategies in AD, and that only one brain-targeted nanoparticle therapy is approved overall (NanoTherm®, for brain cancer), not AD.
## Methods
- This is a review article, not an original experimental study.
- The authors report a comprehensive literature search using PubMed and Google Scholar, with keywords including nanoparticles, Alzheimer’s disease, in vitro studies, in vivo studies, encapsulated drug, surface functionalization, stimuli-responsive, focused ultrasound, and magnetic nanoparticles.
- They selected articles published preferably after 2020, requiring in vitro and/or in vivo studies, direct investigation of the BBB and/or AD, and positive or relevant experimental results.
## Limitations
- The paper states that many approaches remain limited by clinical translation barriers, including long-term safety, chronic toxicity, immunogenicity, quality control in large-scale production, regulatory hurdles, pricing, and off-target effects.
- It also states that animal models do not fully reproduce human AD, and that mice and rats “neither naturally nor experimentally induced develop AD” in the same way as humans; this limits translation to patients.
- Evident from the text: the article is a narrative review rather than a systematic review or meta-analysis, so the evidence synthesis is broader and less standardized than a formal systematic method.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures



![Figure 4 Exosome’s structure. Adapted from [112,113]. This image was created with the software Canvas (https://www.canva.com/).](https://figures.cochat.ai/paper-figures/7438045ae5ad436aa1d8a167dd97995f/advances-in-strategies-to-transport-nanoparticles-across-the-bloodbrain-barrier-figure-4.jpg)
Verification
Claims the paper makes
87 Valid · 3 Not valid · 56 Not checked · 33 Own results and interpretations
Every source the paper cites for this claim was checked and supports it.
In the paper
“This protective barrier limits the entry of foreign substances, including drugs, into the central nervous system.”
- Also stated in: § 2. Challenges in Drug Delivery to the Brain · plain
“Although of the utmost importance for the existence of a stable and safe environment and the maintenance of its homeostasis, the BBB limits the action of drugs in the brain [6].”
§ Advances in Strategies to Transport Nanoparticles Across the Blood–Brain Barrier for Drug Delivery into the Brain for the Treatment of Alzheimer’s Disease > Abstract
What the sources say
- Supportedcites [6] Wu, 2023, The blood-brain barrier: Structure, regulation, and drug delivery, Signal Transduct. Target. Ther. source
The ‘Anatomical structure of the BBB’ section states that the barrier isolates foreign substances in the blood from the CNS and limits drugs entering the CNS. The Introduction likewise says an intact BBB impedes most blood-borne substances and excludes many drugs from the brain. (LLM, conf=0.95)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § 2. Challenges in Drug Delivery to the Brain · plain
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Disrupting the BBB, which consists of opening the TJs of the brain using non-invasive physical methods like infusion of noxious agents (e.g., bradykinin that induces vasodilation) or injection of microbubbles (MBs) (small vehicles filled with gas), followed by sonication (e.g., focused ultrasound (FUS) sonication), is another strategy [16].”
§ Advances in Strategies to Transport Nanoparticles Across the Blood–Brain Barrier for Drug Delivery into the Brain for the Treatment of Alzheimer’s Disease > 2. Challenges in Drug Delivery to the Brain > Transport Mechanisms Across the BBB
What the sources say
- Partly supportedcites [16] Pardridge, W.M. (2022). A Historical Review of Brain Drug Delivery. Pharmaceutics, 14. sourceExperimental — accuracy not yet measured
The Introduction describes BBB disruption by intra-arterial infusion of noxious agents or intravenous microbubble injection followed by brain sonication. Sections 4.2 and 4.3 support tight-junction opening with focused ultrasound and microbubbles. But §4.3 describes these approaches as requiring operating-room treatment, not as non-invasive; §4.1 discusses bradykinin and its analogue as biochemical agents rather than non-invasive physical methods. Page numbers were not provided. (LLM, conf=0.88)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“The main challenges related to intranasal administration lie in the transition from in vitro and animal models to humans due to the anatomical differences in the nasal cavity [15].”
§ Advances in Strategies to Transport Nanoparticles Across the Blood–Brain Barrier for Drug Delivery into the Brain for the Treatment of Alzheimer’s Disease > 2. Challenges in Drug Delivery to the Brain > Transport Mechanisms Across the BBB
What the sources say
- Supportedcites [15] Koo, 2024, Recent Advances in Intranasal Administration for Brain-Targeting Delivery: A Comprehensive Review of Lipid-Based Nanoparticles and Stimuli-Responsive Gel Formulations, Int. J. Nanomed. source
The “Differences Between in-vivo and in-vitro Models” section identifies anatomical differences between humans and animals as a challenge to extrapolating results from preclinical intranasal models to humans. It explicitly describes a translational gap, matching the cited claim. (LLM, conf=0.90)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“This barrier is responsible for the regulation of molecule influx and efflux into and out of the brain.”
§ Advances in Strategies to Transport Nanoparticles Across the Blood–Brain Barrier for Drug Delivery into the Brain for the Treatment of Alzheimer’s Disease > 2. Challenges in Drug Delivery to the Brain
What the sources say
- Supportedcites [6] Wu, 2023, The blood-brain barrier: Structure, regulation, and drug delivery, Signal Transduct. Target. Ther. source
The Introduction says the BBB controls the entrance and expulsion of molecules between the vascular compartment and the brain. The “Physiology of the BBB” section also describes its regulation of molecular exchange between blood and brain tissue. (LLM, conf=0.94)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“However, prolonged BBB disruption associated with long-term treatment raises safety concerns, as it may facilitate neurotoxic effects in the brain [14].”
§ Advances in Strategies to Transport Nanoparticles Across the Blood–Brain Barrier for Drug Delivery into the Brain for the Treatment of Alzheimer’s Disease > 2. Challenges in Drug Delivery to the Brain > Transport Mechanisms Across the BBB
What the sources say
- Partly supportedcites [14] Poudel, P., and Park, S. (2022). Recent Advances in the Treatment of Alzheimer’s Disease Using Nanoparticle-Based Drug Delivery Systems. Pharmaceutics, 14. sourceExperimental — accuracy not yet measured
Section 5.3 (page unavailable) raises uncertainty about the safety of repetitive and prolonged BBB opening, supporting the concern about long-term disruption. The available passage ends before naming a possible effect; Section 8 discusses nanoparticle-induced neurotoxicity but does not establish that prolonged BBB opening facilitates it. (LLM, conf=0.76)
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
60 more claims · 28 with their cited sources checked
Create a free account to see all 179 claims and to verify the 23 references still open.
- Probably not a substantial claim. 45
- It may state two separate claims as one. 88
Citations
Cites
Shape effects of filaments versus spherical particles in flow and drug delivery
Geng, Y., Dalhaimer, P., Cai, S., Tsai, R., Tewari, M., Minko, T., & Discher, D. E. (2007) · Nature Nanotechnology · doi:10.1038/nnano.2007.70 · Cited by 2,565 · cited 1×
“Consequently, by tailoring NPs’ shape, researchers can enhance transcytosis across the BBB, making shape another crucial parameter to consider during NPs design and production [32,35].”
The blood–brain barrier: Structure, regulation and drug delivery
Wu, D., Chen, Q., Chen, X., Han, F., Chen, Z., & Wang, Y. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01481-w · Cited by 1,906 · cited 5×
“Their membrane is negatively charged and allows the passage of small lipophilic molecules and specific substances via transporters present in their surface [6].”
InfluentialA blood–brain barrier overview on structure, function, impairment, and biomarkers of integrity
Kadry, H., Noorani, B., & Cucullo, L. (2020) · Fluids and Barriers of the CNS · doi:10.1186/s12987-020-00230-3 · Cited by 1,853 · cited 3×
“Carrier-mediated transport (CMT) refers to the transport of a variety of molecules facilitated by membrane-bound proteins entitled solute carrier (SLC) transporters [5].”
InfluentialSaraiva, C., Praça, C., Ferreira, R., Santos, T., Ferreira, L., & Bernardino, L. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2016.05.044 · Cited by 1,609 · cited 1×
“As a result, most of the NPs studied for brain delivery have between moderate ( − 1 mV to − 15 mV) and high ( − 15 mV to –45 mV) negative ZP [28].”
Nanoparticles as drug delivery systems
Wilczewska, A. Z., Niemirowicz, K., Markiewicz, K. H., & Car, H. (2012) · Pharmacological Reports · doi:10.1016/s1734-1140(12)70901-5 · Cited by 1,445 · cited 2×
“Therefore, they have proven to be highly relevant in the AD context as they provide a protective vehicle to carry and deliver therapeutic agents to the brain safely [8].”
Zhang, J., Zhang, Y., Wang, J., Xia, Y., Zhang, J., & Chen, L. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01911-3 · Cited by 1,138 · cited 1×
“However, the heterogeneity of these hallmarks cannot be fully comprehended in the light of a single hypothesis [4].”
Lamptey, R. N. L., Chaulagain, B., Trivedi, R., Gothwal, A., Layek, B., & Singh, J. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23031851 · Cited by 900 · cited 1×
“Some of the most common NDs are Alzheimer’s Disease (AD), Parkinson’s disease, spinal system atrophy, Huntington’s disease, amyotrophic lateral sclerosis, motor neuron disease, and spinocerebellar ataxia [2].”
The blood-brain barrier in aging and neurodegeneration
Knox, E. G., Aburto, M. R., Clarke, G., Cryan, J. F., & O’Driscoll, C. M. (2022) · Molecular Psychiatry · doi:10.1038/s41380-022-01511-z · Cited by 738 · cited 1×
“These can include increased paracellular permeability by loss of TJs, degradation of ECs and pericytes, modification in thickness of the basement membrane, astrocyte degeneration, changes in the expression of transporters/receptors present in the BBB, and so forth [41].”
Mendes, B. B., Conniot, J., Avital, A., Yao, D., Jiang, X., Zhou, X., Sharf-Pauker, N., Xiao, Y., Adir, O., Liang, H., et al. (2022) · Nature Reviews Methods Primers · doi:10.1038/s43586-022-00104-y · Cited by 719 · cited 1×
“…expression of specific genes by inserting a functional gene copy to be expressed (e.g., mRNA) and even amplify, surpress, or correct gene expression, consequently resulting in gain or loss of function (e.g., clustered regularly interspaced short palindromic repeats (CRISPR)/Cas systems) [98,99].”
Dendrimers as Nanocarriers for Nucleic Acid and Drug Delivery in Cancer Therapy
Palmerston Mendes, L., Pan, J., & Torchilin, V. (2017) · Molecules · doi:10.3390/molecules22091401 · Cited by 701 · cited 1×
“Therefore, incorporating genetic material into NPs presents an appealing approach to overcome these challenges, since they can protect nucleic acid molecules as well as transport them to the desired locations [87,100].”
The blood-brain barrier: Physiology and strategies for drug delivery
Pandit, R., Chen, L., & Götz, J. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2019.11.009 · Cited by 651 · cited 2×
“Small lipophilic molecules, generally with a molecular weight under 400 Da and less than 8 hydrogen bonds, and gases, such as O 2 and CO 2 , can easily cross the ECs and reach the brain, defining the transcellular diffusion [17].”
Particle shape enhances specificity of antibody-displaying nanoparticles
Barua, S., Yoo, J.-W., Kolhar, P., Wakankar, A., Gokarn, Y. R., & Mitragotri, S. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1216893110 · Cited by 523 · cited 2×
“Consequently, by tailoring NPs’ shape, researchers can enhance transcytosis across the BBB, making shape another crucial parameter to consider during NPs design and production [32,35].”
Hersh, A. M., Alomari, S., & Tyler, B. M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23084153 · Cited by 478 · cited 1×
“Therefore, optimizing ligand concentration is essential [43].”
Magnetic nanoparticles in biomedical applications: A review
Materón, E. M., Miyazaki, C. M., Carr, O., Joshi, N., Picciani, P. H. S., Dalmaschio, C. J., Davis, F., & Shimizu, F. M. (2021) · Applied Surface Science Advances · doi:10.1016/j.apsadv.2021.100163 · Cited by 456 · cited 1×
“The choice of method relies on the specific biomedical application, since each technique enables the synthesis of MNPs with particular size, shape and physicochemical properties [119,120].”
Application of Light Scattering Techniques to Nanoparticle Characterization and Development
Carvalho, P. M., Felício, M. R., Santos, N. C., Gonçalves, S., & Domingues, M. M. (2018) · Frontiers in Chemistry · doi:10.3389/fchem.2018.00237 · Cited by 402 · cited 1×
“It measures the potential in a diffusive layer that involves the Stern’s layer (the first ion layer formed on the NPs’ surface) under the application of an electrical field [26].”
Distinguishing Alzheimer’s disease from other major forms of dementia
Karantzoulis, S., & Galvin, J. E. (2011) · Expert Review of Neurotherapeutics · doi:10.1586/ern.11.155 · Cited by 385 · cited 1×
“Coupled with the inherent socioeconomic impact derived from the health care system, there is an urgent need for effective therapeutic solutions [3].”
Functionalized Nanomaterials Capable of Crossing the Blood–Brain Barrier
Zha, S., Liu, H., Li, H., Li, H., Wong, K.-L., & All, A. H. (2024) · ACS Nano · doi:10.1021/acsnano.3c10674 · Cited by 378 · cited 5×
“…other types of NPs; (ii) application of an external magnet field to guide MNPs as desired and disrupt temporarily the endothelial cell–cell junctions, facilitating their transport into the brain; and (iii) use of a low radiofrequency field which can also reversible and locally open the BBB [78].”
InfluentialHou, K., Zhao, J., Wang, H., Li, B., Li, K., Shi, X., Wan, K., Ai, J., Lv, J., Wang, D., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-18525-2 · Cited by 373 · cited 1×
“Hou et al. [73] fabricated gold NPs decorated with a tripeptide antioxidant, glutathione, to protect tissues from ROS damage and enantioselectively prevent A β aggregation.”
Wang, H., Sui, H., Zheng, Y., Jiang, Y., Shi, Y., Liang, J., & Zhao, L. (2019) · Nanoscale · doi:10.1039/c9nr01255a · Cited by 324 · cited 2×
“[116] BBB-Blood-brain barrier; OA-osteoarthritis; Qc-quercetin; SD-Sprague Dawley.”
InfluentialThe Effect of Nanoparticle Size on the Ability to Cross the Blood–Brain Barrier: An In Vivo Study
Betzer, O., Shilo, M., Opochinsky, R., Barnoy, E., Motiei, M., Okun, E., Yadid, G., & Popovtzer, R. (2017) · Nanomedicine · doi:10.2217/nnm-2017-0022 · Cited by 301
Blood-brain barrier–penetrating siRNA nanomedicine for Alzheimer’s disease therapy
Zhou, Y., Zhu, F., Liu, Y., Zheng, M., Wang, Y., Zhang, D., Anraku, Y., Zou, Y., Li, J., Wu, H., et al. (2020) · Science Advances · doi:10.1126/sciadv.abc7031 · Cited by 300
Blood-Brain Barrier Overview: Structural and Functional Correlation
Alahmari, A. (2021) · Neural Plasticity · doi:10.1155/2021/6564585 · Cited by 299 · cited 2×
“Among the latter, astroglia (astrocytes) and microglia are particularly relevant [9].”
Sánchez-López, E., Ettcheto, M., Egea, M. A., Espina, M., Cano, A., Calpena, A. C., Camins, A., Carmona, N., Silva, A. M., Souto, E. B., et al. (2018) · Journal of Nanobiotechnology · doi:10.1186/s12951-018-0356-z · Cited by 291
Park, H., Oh, J., Shim, G., Cho, B., Chang, Y., Kim, S., Baek, S., Kim, H., Shin, J., Choi, H., et al. (2019) · Nature Neuroscience · doi:10.1038/s41593-019-0352-0 · Cited by 272 · cited 1×
“On the other hand, Li et al. [103] and Zhou et al. [106] used PNPs, Park et al. [108] a peptide-based nanocomplex, and Lopez-Barbosa et al. [107], Wang et al. [109], and Carrillo-Jimenez et al. [110] used inorganic NPs.”
Characterization of Nanomaterials
Mudalige, T., Qu, H., Van Haute, D., Ansar, S. M., Paredes, A., & Ingle, T. (2019) · Nanomaterials for Food Applications · doi:10.1016/b978-0-12-814130-4.00011-7 · Cited by 261
The Impact of Disease Comorbidities in Alzheimer’s Disease
Santiago, J. A., & Potashkin, J. A. (2021) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2021.631770 · Cited by 259 · cited 1×
“However, by sharing some of the regulatory pathways with AD, it has potential in treating the disease [75].”
Exosome-Based Drug Delivery: Translation from Bench to Clinic
Koh, H. B., Kim, H. J., Kang, S.-W., & Yoo, T.-H. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15082042 · Cited by 259 · cited 3×
“[112,113].”
Fan, S., Zheng, Y., Liu, X., Fang, W., Chen, X., Liao, W., Jing, X., Lei, M., Tao, E., Ma, Q., et al. (2018) · Drug Delivery · doi:10.1080/10717544.2018.1461955 · Cited by 258
Nance, E., Timbie, K., Miller, G. W., Song, J., Louttit, C., Klibanov, A. L., Shih, T.-Y., Swaminathan, G., Tamargo, R. J., Woodworth, G. F., et al. (2014) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.06.031 · Cited by 252
Andrade, S., Ramalho, M. J., Loureiro, J. A., & Pereira, M. D. C. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20092313 · Cited by 240 · cited 2×
“Preclinical studies in AD model rats also demonstrated its anti-inflammatory and antioxidant effects and ability to decrease A β and plaque levels [77].”
Self-citationQi, Y., Guo, L., Jiang, Y., Shi, Y., Sui, H., & Zhao, L. (2020) · Drug Delivery · doi:10.1080/10717544.2020.1762262 · Cited by 239 · cited 1×
“Qi et al. [115] produced plasma-derived exosomes (by gradient ultracentrifugation) packed with Qc (Exo-Que) with an average of 150 nm and tested their performance in Okadaic acid (OA)-induced AD mice.”
Ceña, V., & Játiva, P. (2018) · Nanomedicine · doi:10.2217/nnm-2018-0139 · Cited by 232 · cited 1×
“Studies assure the safety of NPs with diameters above 100 nm [23]; however, to be able to cross the BBB, the literature indicates that NPs should be smaller than 200 nm [24].”
A Historical Review of Brain Drug Delivery
Pardridge, W. M. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14061283 · Cited by 219 · cited 1×
“…the TJs of the brain using non-invasive physical methods like infusion of noxious agents (e.g., bradykinin that induces vasodilation) or injection of microbubbles (MBs) (small vehicles filled with gas), followed by sonication (e.g., focused ultrasound (FUS) sonication), is another strategy [16].”
Ohta, S., Kikuchi, E., Ishijima, A., Azuma, T., Sakuma, I., & Ito, T. (2020) · Scientific Reports · doi:10.1038/s41598-020-75253-9 · Cited by 207 · cited 1×
“Ohta et al. [84] investigated the effect of NP size on their delivery into the brain, assisted by FUS-induced BBB opening, using AuNPs of 3, 15, and 120 nm diameter.”
Han, Y., Gao, C., Wang, H., Sun, J., Liang, M., Feng, Y., Liu, Q., Fu, S., Cui, L., Gao, C., et al. (2021) · Bioactive Materials · doi:10.1016/j.bioactmat.2020.08.017 · Cited by 197
Brown, T. D., Habibi, N., Wu, D., Lahann, J., & Mitragotri, S. (2020) · ACS Biomaterials Science & Engineering · doi:10.1021/acsbiomaterials.0c00743 · Cited by 182 · cited 1×
“Another study, using in vitro Transwell models, showed that nonspherical NPs exhibit reduced transport compared to their spherical 200 nm diameter counterparts, suggesting that transcytosis could be affected by the shape [34].”
Loureiro, J. A., Gomes, B., Fricker, G., Coelho, M. A. N., Rocha, S., & Pereira, M. C. (2016) · Colloids and Surfaces B: Biointerfaces · doi:10.1016/j.colsurfb.2016.04.041 · Cited by 179
Self-citationLiposomal delivery of natural product: A promising approach in health research
Islam Shishir, M. R., Karim, N., Gowd, V., Zheng, X., & Chen, W. (2019) · Trends in Food Science & Technology · doi:10.1016/j.tifs.2019.01.013 · Cited by 178 · cited 1×
“Since their discovery, liposomes have been the most common DDS studied for a broad number of drugs [37].”
Koo, J., Lim, C., & Oh, K. T. (2024) · International Journal of Nanomedicine · doi:10.2147/ijn.s439181 · Cited by 174 · cited 2×
“This is relevant, given the low brain-targeting efficiency and route-dependent disease selectivity, which still require further studies to be validated [15].”
Padín-González, E., Lancaster, P., Bottini, M., Gasco, P., Tran, L., Fadeel, B., Wilkins, T., & Monopoli, M. P. (2022) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2022.882363 · Cited by 166 · cited 1×
“…NPs can be produced either by blending PLGA with PLGA-PEG copolymer or by using amine-PEG and coupling through the PLGA carboxylic groups, resorting to EDC/NHS, whilst thiol-PEG-amine is used to attach carboxylic groups to gold NPs and silane-PEG-carboxylic for amine groups in silica NPs [46,63].”
Focused ultrasound/microbubbles-assisted BBB opening enhances LNP-mediated mRNA delivery to brain
Ogawa, K., Kato, N., Yoshida, M., Hiu, T., Matsuo, T., Mizukami, S., Omata, D., Suzuki, R., Maruyama, K., Mukai, H., et al. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.05.042 · Cited by 161 · cited 1×
“Ogawa et al. [83] also used MB-assisted FUS BBB opening to investigate the intravenous delivery of encapsulated mRNA in lipid NPs (mRNA-LNPs) to the brain.”
Wang, J., Li, Z., Pan, M., Fiaz, M., Hao, Y., Yan, Y., Sun, L., & Yan, F. (2022) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2022.114539 · Cited by 161 · cited 2×
“Therefore, inappropriate conditions could result in transient inflammatory responses, flash edema, and even intracerebral hemorrhage [78,80].”
Kong, L., Li, X.-T., Ni, Y.-N., Xiao, H.-H., Yao, Y.-J., Wang, Y.-Y., Ju, R.-J., Li, H.-Y., Liu, J.-J., Fu, M., et al. (2020) · International Journal of Nanomedicine · doi:10.2147/ijn.s239608 · Cited by 158 · cited 1×
“Kong et al. [49] produced osthole-loaded Tf-modified liposomes with a particle size of 104.28 ± 3.76 nm, adequate for BBB crossing, a PdI of 0.194 ± 0.009 (<0.2), indicating a monodisperse sample, and a ZP of − 6.95 ± 0.56 mV, a moderate negative value.”
InfluentialZhong, G., Long, H., Zhou, T., Liu, Y., Zhao, J., Han, J., Yang, X., Yin, Y., Chen, F., & Shi, S. (2022) · Biomaterials · doi:10.1016/j.biomaterials.2022.121690 · Cited by 158 · cited 1×
“…species; RVG29—rabies virus glycoprotein 29; TR@CPL—platelet membrane hybrid double drug-loaded liposomes; S@A-NPs—simvastatin-loaded Angiopep-2-anchored nanoparticles. https://doi.org/10.3390/ph19050685 In this case, too, Zhong et al. [53] did not resort to encapsulating therapeutic molecules.”
InfluentialExosome as drug delivery system: Current advancements
Sharma, V., & Mukhopadhyay, C. D. (2024) · Extracellular Vesicle · doi:10.1016/j.vesic.2023.100032 · Cited by 156 · cited 4×
“[112,113].”
InfluentialDysfunction of ABC transporters at the blood-brain barrier: Role in neurological disorders
Gil-Martins, E., Barbosa, D. J., Silva, V., Remião, F., & Silva, R. (2020) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2020.107554 · Cited by 152
Self-citationArora, S., Layek, B., & Singh, J. (2021) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.0c00461 · Cited by 149 · cited 3×
“Arora et al. [101] demonstrated efficient brain-targeted delivery of pApoE2 using GLUT-1-targeted, dual-functionalized liposomes, in in vitro (Transwell BBB model) and in vivo (C57BL/6 mice) studies.”
InfluentialCano, A., Sánchez-López, E., Ettcheto, M., López-Machado, A., Espina, M., Souto, E. B., Galindo, R., Camins, A., García, M. L., & Turowski, P. (2020) · Nanomedicine · doi:10.2217/nnm-2019-0443 · Cited by 144 · cited 1×
“Among the different polymers, PLGA is the most used [23,39].”
Liu, P., Zhang, T., Chen, Q., Li, C., Chu, Y., Guo, Q., Zhang, Y., Zhou, W., Chen, H., Zhou, Z., et al. (2021) · Advanced Materials · doi:10.1002/adma.202100746 · Cited by 135 · cited 1×
“The mice were injected with the nanocluster at a concentration of 1 mg/kg. Liu et al. [93] produced a ROS-responsive dendrimer with an A β peptide for brain internalization and p-Nrf2 due to its pivotal role in cellular redox homeostasis.”
The Art of PEGylation: From Simple Polymer to Sophisticated Drug Delivery System
Makharadze, D., del Valle, L. J., Katsarava, R. D., & Puiggalí, J. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26073102 · Cited by 135
PEGylated PLGA nanoparticles: unlocking advanced strategies for cancer therapy
Kesharwani, P., Kumar, V., Goh, K. W., Gupta, G., Alsayari, A., Wahab, S., & Sahebkar, A. (2025) · Molecular Cancer · doi:10.1186/s12943-025-02410-x · Cited by 132 · cited 1×
“Kesharwani et al. [64] fabricated PEG-PLGA NPs by mixing both polymers in an organic solvent.”
Jin, Y., Xu, A., Yao, Li, Jin, Y., & Ying, J. (2012) · International Journal of Nanomedicine · doi:10.2147/ijn.s32188 · Cited by 132
The barrier and interface mechanisms of the brain barrier, and brain drug delivery
Zhang, S., Gan, L., Cao, F., Wang, H., Gong, P., Ma, C., Ren, L., Lin, Y., & Lin, X. (2022) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2022.09.017 · Cited by 129 · cited 1×
“Together, they form a symbiotic relation to protect the brain from harmful substances [12,13].”
Yang, L., Yin, T., Liu, Y., Sun, J., Zhou, Y., & Liu, J. (2016) · Acta Biomaterialia · doi:10.1016/j.actbio.2016.09.010 · Cited by 124 · cited 1×
“The same concentration of NPs labeled with a fluorescent dye was used for the in vivo distribution, and NIR was applied for 5 min at 0.5, 1, 2, 4, and 8 h. Yang et al. [91] functionalized the mesoporous silica NPs (MSN) with AuNPs by linking with 4-carboxyphenylboronic acid.”
InfluentialPoudel, P., & Park, S. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14040835 · Cited by 124 · cited 5×
“PLGA NPs’ popularity is attributed to their unique particularities: controlled and sustained release profile, low toxicity, biocompatibility with cells and tissues, easy production, and approval by the Food and Drug Administration (FDA) and European Medicines Agency (EMA) [14,23].”
InfluentialLiu, Y., Gong, Y., Xie, W., Huang, A., Yuan, X., Zhou, H., Zhu, X., Chen, X., Liu, J., Liu, J., et al. (2020) · Nanoscale · doi:10.1039/c9nr09713a · Cited by 123 · cited 1×
“As investigated in the last example described, Liu et al. [85] also used MBs combined with FUS.”
Near‐Infrared Switchable Fullerene‐Based Synergy Therapy for Alzheimer's Disease
Du, Z., Gao, N., Wang, X., Ren, J., & Qu, X. (2018) · Small · doi:10.1002/smll.201801852 · Cited by 121 · cited 1×
“Du et al. [97] designed UCNP conjugated with C 60 and A β -target peptide KLVFF (UCNP@C 60 -pep) as a near-infrared-switchable nanoplatform.”
Ding, H., Sagar, V., Agudelo, M., Pilakka-Kanthikeel, S., Atluri, V. S. R., Raymond, A., Samikkannu, T., & Nair, M. P. (2014) · Nanotechnology · doi:10.1088/0957-4484/25/5/055101 · Cited by 119 · cited 1×
“For instance, Ding et al. [121] produced multifunctional liposomal magnetic nanocarriers functionalized with Tf.”
Amin, F. U., Hoshiar, A. K., Do, T. D., Noh, Y., Shah, S. A., Khan, M. S., Yoon, J., & Kim, M. O. (2017) · Nanoscale · doi:10.1039/c7nr00772h · Cited by 118
Chen, Y., He, Y., Han, J., Wei, W., & Chen, F. (2023) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2023.1258640 · Cited by 116 · cited 3×
“These mechanisms are often perceived as a “vicious cycle”: these alterations initiate BBB breakdown that disrupts the brain’s normal activity, triggering progressive synaptic and neuronal dysfunction, which in turn further compromises the barrier [40].”
InfluentialBiodegradable and Stimuli-Responsive Nanomaterials for Targeted Drug Delivery in Autoimmune Diseases
Parvin, N., Joo, S. W., & Mandal, T. K. (2025) · Journal of Functional Biomaterials · doi:10.3390/jfb16010024 · Cited by 115 · cited 1×
“Internal stimuli include variations in pH, redox state, or increased levels of specific enzymes, while external triggers may involve temperature, magnetic fields, ultrasound, electric fields, or light [86].”
The Art of PEGylation: "From Simple Polymer to Sophisticated Drug Delivery System"
Makharadze, D., del Valle, L. J., Katsarava, R., & Puiggalí, J. (2025) · doi:10.20944/preprints202502.0191.v1 · Cited by 109
Wang, Y., Wang, X., Xie, R., Burger, J. C., Tong, Y., & Gong, S. (2022) · Advanced Materials · doi:10.1002/adma.202208018 · Cited by 95 · cited 1×
“On the other hand, Li et al. [103] and Zhou et al. [106] used PNPs, Park et al. [108] a peptide-based nanocomplex, and Lopez-Barbosa et al. [107], Wang et al. [109], and Carrillo-Jimenez et al. [110] used inorganic NPs.”
Zhao, J., Yin, F., Ji, L., Wang, C., Shi, C., Liu, X., Yang, H., Wang, X., & Kong, L. (2020) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.0c11064 · Cited by 88
Lin, R., Jin, L., Xue, Y., Zhang, Z., Huang, H., Chen, D., Liu, Q., Mao, Z., Wu, Z., & Tao, Q. (2024) · Advanced Science · doi:10.1002/advs.202306675 · Cited by 85 · cited 1×
“Lin et al. [66] designed a multidrug therapy with rapamycin for enhancing autophagy and reducing AD pathological proteins and TPPU to prevent glial cell reactivation and alleviate cognitive deficits derived from AD.”
Nanotechnology to improve the Alzheimer’s disease therapy with natural compounds
Ramalho, M. J., Andrade, S., Loureiro, J. A., & do Carmo Pereira, M. (2020) · Drug Delivery and Translational Research · doi:10.1007/s13346-019-00694-3 · Cited by 75 · cited 3×
“Among the different polymers, PLGA is the most used [23,39].”
Self-citationZhu, H., Allwin, C., Bassous, M. G., & Pouliopoulos, A. N. (2024) · Journal of Neuro-Oncology · doi:10.1007/s11060-024-04795-z · Cited by 75 · cited 1×
“Consequently, the BBB becomes more permeable, allowing therapeutic drugs to pass more easily from the bloodstream into the brain tissue [80,81].”
Yusuf, M., Khan, M., Alrobaian, M. M., Alghamdi, S. A., Warsi, M. H., Sultana, S., & Khan, R. A. (2021) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2020.102214 · Cited by 72 · cited 1×
“…NPs can be produced either by blending PLGA with PLGA-PEG copolymer or by using amine-PEG and coupling through the PLGA carboxylic groups, resorting to EDC/NHS, whilst thiol-PEG-amine is used to attach carboxylic groups to gold NPs and silane-PEG-carboxylic for amine groups in silica NPs [46,63].”
Drug Delivery Systems as a Strategy to Improve the Efficacy of FDA-Approved Alzheimer’s Drugs
Nunes, D., Loureiro, J. A., & Pereira, M. C. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14112296 · Cited by 68 · cited 2×
“Even the FDA and EMA-approved drugs to treat AD have been reported to manifest limitations (e.g., side effects, ineffective passage across the BBB, poor bioavailability, pharmacokinetics, and pharmacodynamics) that have been shown to be overcome by their employment in NPs [7].”
Self-citationDel Amo, L., Cano, A., Ettcheto, M., Souto, E. B., Espina, M., Camins, A., García, M. L., & Sánchez-López, E. (2021) · Applied Sciences · doi:10.3390/app11094305 · Cited by 67 · cited 3×
“The functionalization can be categorized into pre-transcytosis (before crossing the BBB cells) to increase the half-life’s circulation time in the blood; transcytosis to improve the passage across the BBB; and post-transcytosis to direct the NPs to the damaged nerve cells [30].”
InfluentialArora, S., Kanekiyo, T., & Singh, J. (2022) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2022.03.203 · Cited by 67 · cited 1×
“Arora et al. [65] perceived BDNF as a vital neurotrophin due to its role in neuronal function, cell proliferation, and synaptic plasticity, and conceptualized its delivery via plasmids since the level of this protein is reduced in AD patients.”
Transferrin-functionalized liposomes loaded with vitamin VB12 for Alzheimer’s disease therapy
Andrade, S., Ramalho, M. J., Loureiro, J. A., & Pereira, M. C. (2022) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2022.122167 · Cited by 63 · cited 1×
“However, neutral NPs have a higher ability to permeate the BBB without affecting its integrity and reduce protein adsorption, leading to a longer circulation time, making them the most suitable to be used as brain DDS [29].”
Self-citationJiao, Y., Yang, L., Wang, R., Song, G., Fu, J., Wang, J., Gao, N., & Wang, H. (2024) · Pharmaceutics · doi:10.3390/pharmaceutics16121611 · Cited by 63 · cited 2×
“These functionalized vehicles are frequently labeled as “Trojan horses”, derived from the Greek mythology [11].”
Magnetic Iron Nanoparticles: Synthesis, Surface Enhancements, and Biological Challenges
Vargas-Ortiz, J. R., Gonzalez, C., & Esquivel, K. (2022) · Processes · doi:10.3390/pr10112282 · Cited by 62 · cited 1×
“The choice of method relies on the specific biomedical application, since each technique enables the synthesis of MNPs with particular size, shape and physicochemical properties [119,120].”
Chaves, J. C. S., Dando, S. J., White, A. R., & Oikari, L. E. (2024) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2023.166967 · Cited by 62 · cited 1×
“Impaired function of these types of transporters accelerates AD progression by limiting A β clearance and promoting its accumulation in the brain [20].”
Ding, L., Kshirsagar, P., Agrawal, P., & Murry, D. J. (2025) · Pharmaceutics · doi:10.3390/pharmaceutics17060706 · Cited by 62 · cited 2×
“Examples of those include the glucose transporters (GLUTs) responsible for the transport of glucose for energy purposes [18].”
Lopez-Barbosa, N., Garcia, J. G., Cifuentes, J., Castro, L. M., Vargas, F., Ostos, C., Cardona-Gomez, G. P., Hernandez, A. M., & Cruz, J. C. (2020) · Drug Delivery · doi:10.1080/10717544.2020.1775724 · Cited by 59 · cited 1×
“On the other hand, Li et al. [103] and Zhou et al. [106] used PNPs, Park et al. [108] a peptide-based nanocomplex, and Lopez-Barbosa et al. [107], Wang et al. [109], and Carrillo-Jimenez et al. [110] used inorganic NPs.”
Huo, Q., Shi, Y., Qi, Y., Huang, L., Sui, H., & Zhao, L. (2021) · Materials Science and Engineering: C · doi:10.1016/j.msec.2021.112365 · Cited by 58 · cited 1×
“Huo et al. [114] produced silibinin-loaded macrophage-derived exosomes (Exo-Slb) by differential centrifugation combined with filtration and performed both in vitro and in vivo experiments.”
Nanoparticles toxicity: An overview of its mechanism and plausible mitigation strategies
Sharma, N., Kurmi, B. D., Singh, D., Mehan, S., Khanna, K., Karwasra, R., Kumar, S., Chaudhary, A., Jakhmola, V., Sharma, A., et al. (2024) · Journal of Drug Targeting · doi:10.1080/1061186x.2024.2316785 · Cited by 58 · cited 1×
“This toxicity can be manifested by the generation of ROS, disruption of cell membranes, DNA lesions, etc. [128].”
Functionalization of Nanomaterials: Synthesis and Characterization
Rizvi, M., Gerengi, H., & Gupta, P. (2022) · ACS Symposium Series · doi:10.1021/bk-2022-1418.ch001 · Cited by 55
The role of Na+‐K+‐ATPase in the epileptic brain
Sun, J., Zheng, Y., Chen, Z., & Wang, Y. (2022) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.13893 · Cited by 55 · cited 1×
“K + -ATPase that regulates the influx of sodium and efflux of potassium to maintain an ion gradient across the membrane, whose principal roles consist of the uptake and release of neurotransmitters and cellular excitability [22].”
Zhang, L., Cao, K., Xie, J., Liang, X., Gong, H., Luo, Q., & Luo, H. (2024) · Journal of Nanobiotechnology · doi:10.1186/s12951-024-02543-z · Cited by 53 · cited 1×
“Zhang et al. [72] encapsulated cerium oxide nanocrystals into chemically functionalized NPs (1F12 antibody to specifically bind to all forms of A β 42 and RVG29 to bind to receptors located on the surface of ECs and neurons for RMT) to scavenge ROS and prevent the formation of NFTs and A β plaques.”
Gao, L., Wang, J., & Bi, Y. (2025) · International Journal of Nanomedicine · doi:10.2147/ijn.s549893 · Cited by 52 · cited 6×
“Nevertheless, the complexity of their design and the clinical translation remain obstacles to overcome [87].”
InfluentialYuan, X., Jia, Z., Li, J., Liu, Y., Huang, Y., Gong, Y., Guo, X., Chen, X., Cen, J., & Liu, J. (2021) · Journal of Materials Chemistry B · doi:10.1039/d1tb01290h · Cited by 50 · cited 1×
“Yuan et al. [92] developed a dual-stimuli responsive nanoplatform by bonding NGF and RVG for neuroprotective and targeting effects, respectively.”
Current concepts and molecular pathology of neurodegenerative diseases
Forrest, S. L., & Kovács, G. G. (2024) · Pathology · doi:10.1016/j.pathol.2024.10.006 · Cited by 47 · cited 1×
“Neurodegenerative diseases (NDs) are traditionally defined as disorders with selective and symmetric loss of neurons in motor, sensory, or cognitive systems and distinct involvement of functional systems, defining clinical presentation [1].”
Advancements in nano-based drug delivery systems for therapeutics: a comprehensive review
John, J. (2025) · RSC Pharmaceutics · doi:10.1039/d5pm00179j · Cited by 47 · cited 1×
“Lastly, the chemical composition of the NPs can also influence their ability to cross the BBB, as it plays a crucial role in biocompatibility, biodegradability, and potential toxicity [36].”
Tomitaka, A., Vashist, A., Kolishetti, N., & Nair, M. (2023) · Nanoscale Advances · doi:10.1039/d3na00180f · Cited by 45 · cited 1×
“Due to their unique superparamagnetic properties and diverse functionalities, such as magnetic guidance, heat generation under an alternating magnetic field, and image contrasts in magnetic-based medical imaging systems, these NPs are particularly interesting for CNS disease therapy [117].”
Chen, J., Xiang, P., Duro-Castano, A., Cai, H., Guo, B., Liu, X., Yu, Y., Lui, S., Luo, K., Ke, B., et al. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02426-1 · Cited by 45 · cited 1×
“Chen et al. [70] targeted LRP1 with mid-avidity to bias trafficking toward PACSIN2-mediated transcytosis to promote LRP1 upregulation.”
Rodrigues, R. O., Shin, S.-R., & Bañobre-López, M. (2024) · Journal of Nanobiotechnology · doi:10.1186/s12951-024-02720-0 · Cited by 44 · cited 1×
“…technology, unlike conventional static in vitro models, incorporates endothelial barrier formation, fluid flow, and cell–cell interactions, enabling a more accurate assessment of NPs transport mechanisms and their effects in a realistic model that mimics key features of AD physiology [132].”
Polis, B., & Samson, A. O. (2024) · Journal of Alzheimer's Disease · doi:10.3233/jad-240058 · Cited by 43 · cited 1×
“This limits the actual and real translation to humans; thus, developing realistic models featuring humanized characteristics represents a compelling strategy [131].”
Muolokwu, C. E., Chaulagain, B., Gothwal, A., Mahanta, A. K., Tagoe, B., Lamsal, B., & Singh, J. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1405423 · Cited by 42 · cited 4×
“In the context of AD, it was recently discovered that ApoE isoforms mediate several processes, such as cholesterol transport, neuronal signaling, A β clearance, and synaptic plasticity [98].”
InfluentialImam, F., Mukhopadhyay, S., Kothiyal, P., Alshehri, S., Alharbi, K. S., Afzal, M., Iqbal, M., Khan, M. R., Anwer, M. K., Alanazi, A. A. H., et al. (2024) · Saudi Pharmaceutical Journal · doi:10.1016/j.jsps.2024.102048 · Cited by 40
Nájera-Maldonado, L., Parra-González, M., Peralta-Cuevas, E., Gutierrez-Onofre, A. J., Garcia-Atutxa, I., & Villanueva-Flores, F. (2025) · Pharmaceutics · doi:10.3390/pharmaceutics17091169 · Cited by 40 · cited 1×
“Such electrostatic attraction between the two interfaces (NPs and BBB) leads to the disruption of TJs, and ultimately, the opening or dysfunction of the barrier [27].”
Unveiling the Complex Role of Exosomes in Alzheimer’s Disease
Sun, M., & Chen, Z. (2024) · Journal of Inflammation Research · doi:10.2147/jir.s466821 · Cited by 39 · cited 3×
“…(i) to establish communication between cells and tissues by exchange of their intrinsic content; (ii) as diagnostic biomarkers; (iii) as DDS due to their properties (high stability, minimal immunogenicity, ease in crossing biological barriers, target specific cells or tissues, etc.) [111,112].”
Badr, A., Daily, K. P., Eltobgy, M. M., Estfanous, S. Z. K., Tan, M. H., Kuo, J. C., Whitham, O. D., Carafice, C., Gupta, G., Amer, H. M., et al. (2024) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2024.05.006 · Cited by 38
Kamath, A. P., Nayak, P. G., John, J., Mutalik, S., Balaraman, A. K., & Nandakumar, K. (2024) · Neuropharmacology · doi:10.1016/j.neuropharm.2024.110096 · Cited by 37 · cited 1×
“Three primary mechanisms contribute to this process: (i) macromolecule peroxidation, (ii) A β metal ion redox potential, and (iii) mitochondrial dysfunction [89].”
Iron Oxide Nanoparticle-Incorporated Mesenchymal Stem Cells for Alzheimer’s Disease Treatment
Jung, M., Kim, H., Hwang, J. W., Choi, Y., Kang, M., Kim, C., Hong, J., Lee, N. K., Moon, S., Chang, J. W., et al. (2023) · Nano Letters · doi:10.1021/acs.nanolett.2c03682 · Cited by 36
Gupta, R., Chauhan, A., Kaur, T., Kuanr, B. K., & Sharma, D. (2022) · Nanoscale · doi:10.1039/d2nr02210a · Cited by 35 · cited 1×
“Gupta et al. [122] also used MNPs, intending to investigate a dual magnetic strategy to help the crossing of the BBB. Firstly, an EMF was used to enhance cellular association with the brain ECs, then an altering magnetic field (AMF) was applied to transiently loosen the TJs of the BBB. Results in…”
Li, L., Xiong, Y., Zhang, Y., Yan, Y., Zhao, R., Yang, F., & Xie, M. (2024) · Journal of Controlled Release · doi:10.1016/j.jconrel.2024.09.009 · Cited by 35 · cited 1×
“Li et al. [90] maximized the full potential of the PBNPs.”
Clinical translation of nanomedicines for brain diseases: Current challenges and future directions
Wang, G., Wang, N., Xia, X., Ismail, M., & Shi, B. (2026) · Journal of Controlled Release · doi:10.1016/j.jconrel.2025.114426 · Cited by 33 · cited 5×
“The majority of clinical trials, in addition to being in early phases, are primarily focused on brain tumors, since NDs like AD express multiple and often interrelated pathogenic pathways hindering the discovery of universal therapeutic targets [127].”
InfluentialEngineering brain-derived neurotrophic factor mRNA delivery for the treatment of Alzheimer’s disease
Li, H., Cao, Y., Ye, J., Yang, Z., Chen, Q., Liu, X., Zhang, B., Qiao, J., Tang, Q., Yang, H., et al. (2023) · Chemical Engineering Journal · doi:10.1016/j.cej.2023.143152 · Cited by 32 · cited 2×
“On the other hand, Li et al. [103] and Zhou et al. [106] used PNPs, Park et al. [108] a peptide-based nanocomplex, and Lopez-Barbosa et al. [107], Wang et al. [109], and Carrillo-Jimenez et al. [110] used inorganic NPs.”
Hu, Y., Guo, H., Cheng, S., Sun, J., Du, J., Liu, X., Xiong, Y., Chen, L., Liu, C., Wu, C., et al. (2023) · International Journal of Nanomedicine · doi:10.2147/ijn.s434873 · Cited by 32 · cited 1×
“For the in vivo studies, both L-and D-glutathione gold NPs were injected with a concentration of 25 mg/kg. Hu et al. [74] encapsulated RES, a non-flavonoid found in red wine, almonds, and grapes, due to its potential therapeutic effects on AD.”
Geng, H., Yuan, H., Qiu, L., Gao, D. M., Cheng, Y., & Xing, C. (2020) · Journal of Materials Chemistry B · doi:10.1039/d0tb01863e · Cited by 31 · cited 1×
“Geng et al. [96] designed conjugated polymer-based thermo-responsive micelles (CPMs) loaded with PF.”
Carrillo-Jiménez, A., Puigdellívol, M., Vilalta, A., Venero, J. L., Brown, G. C., George‐Hyslop, P. S., & Burguillos, M. Á. (2018) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2018.00313 · Cited by 29 · cited 1×
“On the other hand, Li et al. [103] and Zhou et al. [106] used PNPs, Park et al. [108] a peptide-based nanocomplex, and Lopez-Barbosa et al. [107], Wang et al. [109], and Carrillo-Jimenez et al. [110] used inorganic NPs.”
Hou, K., Pan, H., Shahpasand‐Kroner, H., Hu, C. J., Abskharon, R. N. N., Seidler, P. M., Mekkittikul, M., Balbirnie, M., Lantz, C., Sawaya, M. R., et al. (2024) · Science Advances · doi:10.1126/sciadv.adl2991 · Cited by 29
Buzulukov, Y. P., Arianova, E. A., Demin, V. F., Safenkova, I. V., Gmoshinski, I. V., & Tutelyan, V. A. (2014) · Biology Bulletin · doi:10.1134/s1062359014030042 · Cited by 27 · cited 1×
“In a study conducted by Buzulukov et al. [42], Ag NPs were able to reach the brain tissue (66.4 ± 5.6 ng of Ag detected in the brain from a dose of 0.1 mg/kg of body weight (BW) for 28 or 14 days).”
InfluentialRecent Advances in the Development of Magnetic Nanoparticles for Biomedical Applications
Monteserín, M., Larumbe, S., Martínez, A. V., Burgui, S., & Francisco Martín, L. (2021) · Journal of Nanoscience and Nanotechnology · doi:10.1166/jnn.2021.19062 · Cited by 27 · cited 1×
“The main applications of these NPs include magnetic hyperthermia, imaging contrast agents, theranostics, and magnetic drug targeting [118].”
Elhabak, M., Salama, A. A. A., & Salama, A. H. (2023) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2023.122588 · Cited by 27
Wang, K., Yang, R., Li, J., Wang, H., Wan, L., & He, J. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1591438 · Cited by 27 · cited 3×
“Other limitations include off-target effects because of drug interaction with unwanted cells, disease heterogeneity demanding biomarker-driven patient classification for a personalized therapy, regulations, pricing, social considerations, and so on [127,129].”
Jiménez, M. T. B., Rivas‐García, L., Sánchez‐González, C., Grosso, G., Lipari, V., Ramírez, L. V., Battino, M. A., Giampieri, F., Quiles, J. L., & Forbes-Hernández, T. Y. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms262110631 · Cited by 25 · cited 1×
“…confirmed its potential since it was able to reduce A β fibrils and even induce A β disaggregation, reshape toxic aggregates into non-toxic, promote autophagy and mitochondrial health by being a sirtuin 1 activator (reducing protein aggregation and oxidative damage), among other benefits [76,77].”
Khonsari, F., Heydari, M., Sharifzadeh, M. S., Valizadeh, H., Dinarvand, R., & Atyabi, F. (2022) · Biomaterials Advances · doi:10.1016/j.bioadv.2022.212827 · Cited by 22 · cited 1×
“Both the loaded therapeutic (rapamycin) and the surface functionalized (Tf) molecules’ rationale used in the NLCs designed by Khonsari et al. [69] have already been explored.”
Pan, T.-T., Sun, Y., Shi, Y.-F., Zhao, M., Khan, N. U., Chen, H., Ji, W., Li, J., Han, L., & Ma, Q. (2025) · Alzheimer s Research & Therapy · doi:10.1186/s13195-025-01840-5 · Cited by 21 · cited 1×
“Pan et al. [68] identified analogous functions in LRP1.”
Zhang, C., Gu, Z., Shen, L., Liu, X., & Lin, H. (2019) · Current Pharmaceutical Biotechnology · doi:10.2174/1389201020666190204141046 · Cited by 20
Rouhi, N., Chakeri, Z., Ghorbani Nejad, B., Rahimzadegan, M., Rafi Khezri, M., Kamali, H., & Nosrati, R. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e37533 · Cited by 20 · cited 2×
“However, effective BBB opening requires combining FUS with systemically administered MBs. MBs are a type of microsphere with diameters ranging from 0.5 to 10 µ m that can be injected intravenously [79].”
InfluentialLee, D., Shen, A. M., Shah, M., Garbuzenko, O. B., & Minko, T. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms251910357 · Cited by 20 · cited 2×
“Lee et al. [102] developed liposomes encapsulating BACE1 siRNA, donepezil, or memantine, as well as their combination as a triple-drug therapy in treating AD.”
Henningfield, C. M., Soni, N., Lee, R. W., Sharma, R. B., Cleland, J. L., & Green, K. N. (2024) · Alzheimer s Research & Therapy · doi:10.1186/s13195-024-01470-3 · Cited by 19 · cited 1×
“Henningfield et al. [67], instead of encapsulating a therapeutic molecule, attached a dendranib that inhibits CSF1R tyrosine kinase to the dendrimers’ surface, D-45113.”
Role of Ion Channels in Alzheimer’s Disease Pathophysiology
Bhoi, R., Mitra, T., Tejaswi, K., Manoj, V., & Ghatak, S. (2025) · The Journal of Membrane Biology · doi:10.1007/s00232-025-00341-8 · Cited by 19 · cited 1×
“Ion channels are essential to sustain a healthy brain function through processes such as the release of neurotransmitters, the generation of action potentials, and the enabling of synaptic plasticity, among others [21].”
Hernández‐Parra, H., Cortés, H., Romero‐Montero, A., et al. (2024) · Carbohydrate Polymers · doi:10.1016/j.carbpol.2024.122121 · Cited by 13
Characterization of nanoparticles
Sarker, S. D., & Nahar, L. (2022) · Advances in Nanotechnology-Based Drug Delivery Systems · doi:10.1016/b978-0-323-88450-1.00011-9 · Cited by 10
Measurement of Transendothelial Electrical Resistance in Blood-Brain Barrier Endothelial Cells
Waithe, O. Y., Peng, X., Childs, E. W., & Tharakan, B. (2024) · Methods in Molecular Biology · doi:10.1007/978-1-0716-3429-5_16 · Cited by 10 · cited 1×
“ECs are highly sealed by TJs that impede the paracellular diffusion of most molecules, besides causing blood vessels to have high transendothelial electrical resistance, which translates to the integrity of the cellular barriers in restraining the passage of substances into the brain [6,10].”
Lin, Y., Wang, Y., Lv, J., Wang, N., Wang, J., & Li, M. (2019) · International Journal of Nanomedicine · doi:10.2147/ijn.s215404 · Cited by 9 · cited 1×
“Lin et al. [94] focused on the crucial role of AChE, which catalyzes the hydrolysis of ACh, in the transmission of nerve impulses at the cholinergic synapses.”
Wang, N., Parsons, T. M., Ren, Y., Pan, Y., Kurti, A., Starling, S. C., Muolokwu, C. E., Singh, J., & Kanekiyo, T. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e39607 · Cited by 9
Attia, R. T., Fahmy, S. A., Abdel‐Latif, R. T., Ateyya, H., Fayed, T. W., & El-Abhar, H. S. (2025) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2025.106803 · Cited by 9
Garg, T., Patel, S., Yadav, D., Dave, V., & Yadav, R. (2024) · Nano-Structures & Nano-Objects · doi:10.1016/j.nanoso.2024.101406 · Cited by 6
Ye, Z., Li, L., Duan, Q., Sheng, X., Zhang, C., Fan, X., Li, Z., & Xiao, L. (2025) · Advanced Healthcare Materials · doi:10.1002/adhm.202502595 · Cited by 6
Tomak, A., Saglam-Metiner, P., Coban, R., Oksel-Karakus, C., & Yesil-Celiktas, O. (2025) · Tissue and Cell · doi:10.1016/j.tice.2025.103080 · Cited by 6 · cited 1×
“Rod-shaped AuNPs exhibited a higher initial capacity to cross the BBB but tended to accumulate near the spheroid’s periphery, with restricted penetration into its core [33].”
Alonso, M., Barcia, E., Negro, S., Paccione, N., Rahmani, M., Montejo, C., García‐García, L., & Fernández-Carballido, A. M. (2025) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2025.106680 · Cited by 5
Research application of immunomodulatory nanomaterials in Alzheimer's disease vaccine development
Guo, J., Zhang, T., Li, Y., Chen, P., Li, M., Yan, Q., & Shao, B. (2025) · Nano Biomedicine and Engineering · doi:10.1016/j.nbe.2025.100007 · Cited by 5 · cited 1×
“To address these challenges, stricter quality control systems and standardized production processes need to be implemented to help minimize batch-to-batch variability, guarantee product reliability, and ensure safe and efficient industrial production [130].”
İğdeli, G., Fritzen, L., Pietrzik, C. U., & Temel, B. A. (2025) · Journal of Biomaterials Science Polymer Edition · doi:10.1080/09205063.2025.2486863 · Cited by 2
Research works printed but not linked: 4
- Dotiwala, A.K., McCausland, C., and Samra, N.S. (2025, October 01). Anatomy, Head and Neck: Blood Brain Barrier, Available online: https://www.ncbi.nlm.nih.gov/books/NBK519556/.
- (2026, April 17). Polymer Nanoparticles—An Overview|ScienceDirect Topics. Available online: https://www.sciencedirect.com/topics/materials-science/polymer-nanoparticles.
- Zhang, 2024, Multifunctional mesoporous nanoselenium delivery of metformin breaks the vicious cycle of neuroinflammation and ROS, promotes microglia regulation and alleviates Alzheimer’s disease, Colloids Surf. B Biointerfaces, 245, 114300
- Mutluay, 2022, Donepezil-loaded PLGA-b-PEG Nanoparticles Enhance the Learning and Memory Function of Beta-Amyloid Rat Model of Alzheimer’s Disease, Arch. Neuropsychiatry, 59, 281
Cited by
Begum, M. Y., Rajkumar, M., Govindaraj, P., Prathap, N., Sudha, P. N., Hamod, M. A., Alotaibi, H., & Uvarajan, D. (2026) · Inflammopharmacology · doi:10.1007/s10787-026-02381-5 · Cited by 1
Targeting Autophagy in Alzheimer's Disease: Role of the AMPK/mTOR Pathway and Drug Repurposing
Dubey, A., Chaurasia, A., Ansari, Z. A., Kushwaha, S. K., Saraf, I., Kashaw, S. K., Swami, R., & Kushwah, V. (2026) · Drug Development Research · doi:10.1002/ddr.70344 · Cited by 1
Metadata
- Authors
- Silva, R., Monteiro, J., Ramalho, M. J., Andrade, S., Loureiro, J. A., & Pereira, M. C.
- Affiliations
- Universidade do Porto (PT)
- Corresponding author
- Loureiro, Joana A.
- Pereira, Maria Carmo
- ORCID
- Venue
- Pharmaceuticals
- Publisher
- MDPI AG
- Published
- 2026-04-27
- Volume
- 19
- Issue
- 5
- Pages
- 685
- ISSN
- 1424-8247 (ISSN-L)
- PMC
- PMC13209752
- OpenAlex
- W7160150054
- Cited by
- 2
- References
- 126
- Citations by year
- 2026: 2
- FWCI
- 0.87
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Pharmaceuticals (publishedVersion, cc-by)
- PubMed (publishedVersion)
- PubMed Central (publishedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- FCT/MCTES (UIDB/00511/2020, UIDP/00511/2020, LA/P/0045/2020)
- Foundation for Science and Technology (M-ERA-NET3/0001/2021)
- Project Nano4Glio (958174)
- European Union (NORTE2030-FEDER-02696100)
- FCT (CEEC-IND/01741/2021)
- Topics
- Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
- Life Sciences › Neuroscience › Neurology › Barrier Structure and Function Studies
- Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
- Keywords
- Alzheimer's disease, blood-brain barrier, engineered nanoparticles, nanoparticle drug delivery, brain drug delivery, clinical translation barriers, neurodegenerative disease treatment
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.